Shaji Kumar, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Shaji Kumar, MD

Shaji Kumar, MD

Healthcare Professional
Consultant
Division of Hematology
Mayo Clinic
200 First St. SW
Rochester, Minnesota, United States

Shaji Kumar is a hematologist in Mayo Clinic, Rochester, Minnesota. Dr. Kumar completed MBBS and clinical residency from All India Institute of Medical Sciences and obtained fellowship in Hematology/ Oncology from Mayo Graduate School of Medicine, Mayo Clinic College of Medicine. His areas of interests are amyloidosis and multiple myeloma. 

The research of Shaji Kumar focuses on development of novel drugs for treatment of myeloma. Dr. Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.

Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes.  

Dr.Kumar’s clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.

 

Representative Publications:

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy 

Natural history of multiple myeloma with de novo del(17p) 

view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close